Matrix metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease

Ophthalmology

Volumn 122, Issue 1, 2015, Pages 62-71

  Aragona, Pasquale ^a   Aguennouz, M'Hammed ^a   Rania, Laura ^a   Postorino, Elisa ^a   Sommario, Margherita Serena ^a   Roszkowska, Anna Maria ^a   De Pasquale, Maria Grazia ^a   Pisani, Antonina ^a   Puzzolo, Domenico ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CASPASE 3; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 6; LOTEPREDNOL ETABONATE; MESSENGER RNA; PROTEIN BCL 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; BIOLOGICAL MARKER; GLUCOCORTICOID; IL6 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TISSUE TRANSGLUTAMINASE 2, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOPATHOLOGY; DRY EYE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MEIBOMIAN GLAND DYSFUNCTION; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SJOEGREN SYNDROME; AGED; CHEMISTRY; CONJUNCTIVA; ENZYMOLOGY; EYELID DISEASES; GENETICS; IMMUNOHISTOCHEMISTRY; LACRIMAL FLUID; MEIBOMIAN GLAND; METABOLISM; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SJOGREN'S SYNDROME;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CASPASE 3; CONJUNCTIVA; EYELID DISEASES; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 9; MEIBOMIAN GLANDS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; QUESTIONNAIRES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SINGLE-BLIND METHOD; SJOGREN'S SYNDROME; TEARS; TRANSGLUTAMINASES;

EID: 84920722580     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.07.048     Document Type: Article

References (53)

1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf 2007;5:75-92.
2. Bron AJ, Yokoi N, Gafney E, Tiffany JM. Predicted phenotypes of dry eye: proposed consequences of its natural history. Ocul Surf 2009;7:78-92.
3. Behrens A, Doyle JJ, Stern L, et al; Dysfunctional Tear Syndrome Study Group. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006;25:900-7.
4. Zoukhri D. Effect of inflammation on lacrimal gland function. Exp Eye Res 2006;82:885-98.
5. Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN Group meeting. Ocul Surf 2013;11:246-58.
6. Chotikavanich S, de Paiva CS, Lee DQ, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci 2009;50:3203-9.
7. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res 2006;83:526-35.
8. Meloni M, De Servi B, Marasco D, Del Prete S. Molecular mechanism of ocular surface damage: application to an in vitro dry eye model on human corneal epithelium. Mol Vis [serial online] 2011;17:113-26. Available at: http://www.molvis.org/molvis/v17/a15/. Accessed July 29, 2014.
9. De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol 2009;2:243-53.
10. Pflugfelder SC, Farley W, Luo L, et al. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Am J Pathol 2005;166:61-71.
11. Tong L, Chen Z, De Paiva CS, et al. Transglutaminase participates in the UVB-induced cell death pathways in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2006;47:4295-301.
12. Chen Z, Tong L, Li Z, et al. Hyperosmolarity-induced cornification of human corneal epithelial cells is regulated by JNK MAPK. Invest Ophthalmol Vis Sci 2008;49:539-49.
13. Png E, Samivelu GK, Yeo SH, et al. Hyperosmolarity-mediated mitochondrial dysfunction requires transglutaminase-2 in human corneal epithelial cells. J Cell Physiol 2011;226:693-9.
14. D'Souza S, Petznick A, Tong L, et al. Comparative analysis of two femtosecond LASIK platforms using iTRAQ quantitative proteomics. Invest Ophthalmol Vis Sci 2014;55:3396-402.
15. Fesus L, Szondy Z. Transglutaminase 2 in the balance of cell death and survival. FEBS Lett 2005;579:3297-302.
16. Campisi A, Bramanti V, Caccamo D, et al. Effect of growth factors and steroids on transglutaminase activity and expression in primary astroglial cell cultures. J Neurosci Res 2008;86:1297-305.
17. Vitali C, Bombardieri S, Jonsson R, et al; European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
18. Bron AJ, Benjamin L, Snibson GR. Meibomian gland disease. Classification and grading of lid changes. Eye (Lond) 1991;5:395-411.
19. Tomlinson A, Bron AJ, Korb DR, et al. The International Workshop on Meibomian Gland Dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci 2011;52:2006-49.
20. Fenga C, Aragona P, Di Nola C, Spinella R. Comparison of ocular surface disease index and tear osmolarity as markers of ocular surface dysfunction in video terminal display workers. Am J Ophthalmol 2014;158:41-8.
21. Aragona P, Rania L, Roszkowska AM, et al. Effects of amino acids enriched tears substitutes on the cornea of patients with dysfunctional tear syndrome [report online]. Acta Ophthalmol 2013;91:e437-44.
22. Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J 1995;21:221-31.
23. Barr JT, Schechtman KB, Fink BA, et al. Corneal scarring in the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) study: baseline prevalence and repeatability of detection. Cornea 1999;18:34-46.
24. Aragona P, Di Stefano G, Ferreri F, et al. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients. Br J Ophthalmol 2002;86:879-84.
25. Nelson DJ, Shimazaki J, Benitez-del-Castillo JM, et al. The International Workshop on Meibomian Gland Dysfunction: report of the Definition and Classification Subcommittee. Invest Ophthalmol Vis Sci 2011;52:1930-7.
26. Aragona P, Rania L, Puzzolo D. The role of inflammation, inflammatory cytokines and ocular surface markers in Dry Eye Syndrome. In: Benitez-del-Castillo JM, Lemp MA, eds. Ocular Surface Disorders. London: JP Medical Publ.; 2013:55-68.
27. Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000;118:1489-96.
28. Higuchi A, Kawakita T, Tsubota K. IL-6 induction in desiccated corneal epithelium in vitro and in vivo. Mol Vis [serial online] 2011;17:2400-6. Available at: http://www.molvis.org/molvis/v17/a261/. Accessed July 29, 2014.
29. Sugaya S, Sakimoto T, Shoji J, Sawa M. Regulation of soluble interleukin-6 (IL-6) receptor release from corneal epithelial cells and its role in the ocular surface. Jpn J Ophthalmol 2011;55:277-82.
30. Musumeci M, Aragona P, Bellin M, et al. Acidic mammalian chitinase in dry eye conditions. Cornea 2009;28:667-72.
31. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci 2004;45:4293-301.
32. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006;26:299-307.
33. Mohan R, Chintala S, Jung J, et al. Matrix metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial regeneration. J Biol Chem 2002;277:2065-72.
34. Raghunath M, Cankay R, Kubitscheck U, et al. Transglutaminase activity in the eye: cross-linking in epithelia and connective tissue structures. Invest Ophthalmol Vis Sci 1999;40:2780-7.
35. Song H, Kim BK, Chang W, et al. Tissue transglutaminase 2 promotes apoptosis of rat neonatal cardiomyocytes under oxidative stress. J Recept Signal Transduct Res 2011;31:66-74.
36. Shine WE, McCulley JP. Meibomian gland triglyceride fatty acid differences in chronic blepharitis patients. Cornea 1996;15:340-6.
37. Green-Church KB, Butovich I, Willcox M, et al. The International Workshop on Meibomian Gland Dysfunction: report of the Subcommittee on Tear Film Lipids and Lipid-Protein Interactions in health and disease. Invest Ophthalmol Vis Sci 2011;52:1979-93.
38. Kuo TF, Tatsukawa H, Matsuura T, et al. Free fatty acids induce transglutaminase 2-dependent apoptosis in hepatocytes via ER stress-stimulated PERK pathways. J Cell Physiol 2012;227:1130-7.
39. Shin S, Cho YP, Jun H, et al. Transglutaminase type 2 in human abdominal aortic aneurysm is a potential factor in the stabilization of extracellular matrix. J Vasc Surg 2013;57:1362-70.
40. Li Z, Xu X, Bai L, et al. Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cells. J Biol Chem 2011;286:21164-72.
41. Yeh S, Song XJ, Farley W, et al. Apoptosis of ocular surface cells in experimentally induced dry eye. Invest Ophthalmol Vis Sci 2003;44:124-9.
42. Gao J, Sana R, Calder V, et al. Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells: effect of cyclosporin A. Invest Ophthalmol Vis Sci 2013;54:4717-33.
43. Contreras-Ruiz L, Ghosh-Mitra A, Shatos MA, et al. Modulation of conjunctival goblet cell function by inflammatory cytokines. Mediators Inflamm 2013;2013:636812.
44. Vermeer PD, Denker J, Estin M, et al. MMP9 modulates tight junction integrity and cell viability in human airway epithelia. Am J Physiol Lung Cell Mol Physiol 2009;296:L751-62.
45. Aragona P, Spinella R, Rania L, et al. Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjögren syndrome. Eur J Ophthalmol 2013;23:368-76.
46. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf 2007;5:163-78.
47. De Paiva CS, Corrales RM, Villarreal AL, et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest Ophthalmol Vis Sci 2006;47:2847-56.
48. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology 1999;106:811-6.
49. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 2004;138:444-57.
50. Bodor N, Loftsson T, Wu WM. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Pharm Res 1992;9:1275-8.
51. Fenga C, Aragona P, Cacciola A, et al. Meibomian gland dysfunction and ocular discomfort in video display terminal workers. Eye (Lond) 2008;22:91-5.
52. Asbell PA, Stapleton FJ, Wickstrom K, et al. The International Workshop on Meibomian Gland Dysfunction: report of the Clinical Trials Subcommittee. Invest Ophthalmol Vis Sci 2011;52:2065-85.
53. Aragona P, Rolando M. Towards a dynamic customised therapy for ocular surface dysfunctions. Br J Ophthalmol 2013;97:955-60.